Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
BeOne Medicines clinical trials
The registry lists 190 studies whose lead sponsor is BeOne Medicines or one of 1 company grouped under it. 46 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.
Keep track of what changes. Save the BeOne Medicines studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to BeOne Medicines.
- BeiGene125 studiesSame company
Something wrong?
- BeOne Medicines64 studiesSame company
Something wrong?
- BeiGene USA, Inc.1 study →Regional office
Something wrong?
Focus areas
Conditions BeOne Medicines leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 190. Browse all 190 →
- A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)RecruitingNCT06943872Phase 3
- A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) MutationsRecruitingNCT07746141Phase 1
- A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395RecruitingNCT07820891Phase 1
- Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-DegraderRecruitingNCT05294731Phase 1/2
- A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell MalignanciesNot yet recruitingNCT07887646Phase 1
- An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid TumorsRecruitingNCT06589596Phase 1
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participants With Severe Hepatic ImpairmentNot yet recruitingNCT07855991Phase 1
- A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell MalignanciesNot yet recruitingNCT07881211Phase 1
- A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United StatesRecruitingNCT07554521Phase 2
- BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseRecruitingNCT07492641Phase 3
- BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsRecruitingNCT06120283Phase 1
- A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)RecruitingNCT07652736
- A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingNCT07043400Phase 3
- A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCCRecruitingNCT07733180Phase 2
- A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy ParticipantsRecruitingNCT07590102Phase 1
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell MalignanciesRecruitingNCT05006716Phase 1/2
- A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg (BGB-16673) in Participants With Moderate and Severe Hepatic ImpairmentNot yet recruitingNCT07856004Phase 1
- A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)RecruitingNCT06742996Phase 3
- A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple MyelomaRecruitingNCT04973605Phase 1/2
- A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.RecruitingNCT06697184Phase 1/2
- A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid TumorsRecruitingNCT05981703Phase 1
- A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingNCT06973187Phase 3
- A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsRecruitingNCT06846671Phase 3
- A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid TumorsRecruitingNCT07181681Phase 1
- An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid MalignanciesRecruitingNCT07619287Phase 1
- A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid TumorsRecruitingNCT07226349Phase 1
- A First-in-Human Study of BG-C0979 in Adults With Advanced Solid TumorsRecruitingNCT07414836Phase 1
- A Study to Investigate the Relative Bioavailability of 2 Tablet Formulations and the Effect of Food on the Pharmacokinetics of BGB-58067 in Healthy ParticipantsRecruitingNCT07712640Phase 1
- An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid TumorsRecruitingNCT07222267Phase 1
- A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaRecruitingNCT07277231Phase 3
- Study Comparing BGB-B2033 With Sorafenib or Lenvatinib in Relapsed Hepatocellular CarcinomaNot yet recruitingNCT07836530Phase 3
- A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Phase 1/2
- Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid TumorsRecruitingNCT06233942Phase 1
- A Study of BG-C477 in Participants With Advanced Solid TumorsRecruitingNCT06596473Phase 1
- A Study of BGB-11417 in Participants With Myeloid MalignanciesRecruitingNCT04771130Phase 1/2
- BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast CancerRecruitingNCT06756932Phase 1
- A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesRecruitingNCT06634589Phase 1/2
- Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid TumorsRecruitingNCT06598800Phase 1
- Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal CancersNot yet recruitingNCT07811271Phase 3
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy ParticipantsRecruitingNCT07005713Phase 1
- A Study of BGB-B455 in Adults With Advanced or Metastatic Solid TumorsRecruitingNCT06803680Phase 1
- A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic LeukemiaNot yet recruitingNCT07770698Phase 1/2
- A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin DiseasesRecruitingNCT07412691Phase 1
- Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström MacroglobulinemiaRecruitingNCT05640102
Sponsor listed in the registry: BeiGene
- Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid TumorsRecruitingNCT03736889Phase 2
Sponsor listed in the registry: BeiGene
- A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid TumorsRecruitingNCT06625593Phase 1
- A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy AdultsCompletedNCT07628881Phase 1
- A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage TumorsActive, not recruitingNCT06257264Phase 1
Sponsor listed in the registry: BeiGene
- A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström MacroglobulinemiaActive, not recruitingNCT05952037Phase 2
- A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaActive, not recruitingNCT05100862Phase 3